ViiV Healthcare Questions Natco's Ability To Make And Sell Selzentry In India; Stays Silent On Voluntary License Issue
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - ViiV Healthcare - formed by GlaxoSmithKline Pharmaceuticals Plc and Pfizer Inc. in 2009 to work on a range of HIV/AIDS medications - struck back with a volley of questions to Natco Pharma Ltd., which had sought a voluntary license in December 2010 to manufacture generic versions of Selzentry
You may also be interested in...
Merck And Cipla Bury Differences To Co-market Raltegravir In India
Merck agreed to co-market its patented HIV product raltegravir in India with rival Cipla, bringing to end what had started as an attempt for a voluntary license and could have veered toward a compulsory license.
ViiV May Dodge Compulsory License For Celsentri In India; Commits To Competitive Price Via Local Ally
Unfazed by the recent compulsory license granted to Natco for Bayer’s Nexavar, ViiV closes in on a local partnership.
ViiV May Dodge Compulsory License For Celsentri In India; Commits To Competitive Price Via Local Ally
Unfazed by the recent compulsory license granted to Natco for Bayer’s Nexavar, ViiV closes in on a local partnership.